Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 24, 2023 Filed Jan 25, 2023 21:08 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 2,511 | $312.29 | $784,160.19 |
DisclosureSEC source: 0001209191-23-004816 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,364 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $312.29 (range $312.00 to $312.92). Read SEC document |
| January 24, 2023 Filed Jan 25, 2023 21:08 UTC |
Lee YuchunDirector
|
Exercise / conversionCommon Stock | 4,000 | $72.14 | $288,560.00 |
DisclosureSEC source: 0001209191-23-004816 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:08 UTC |
Lee YuchunDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,129 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-004816 · doc4.xml · derivative · entry 6 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,429 Underlying: Common Stock · 2,129 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:08 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 2,129 | $312.02 | $664,290.58 |
DisclosureSEC source: 0001209191-23-004816 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $312.02 (range $312.00 to $312.17). Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:08 UTC |
Lee YuchunDirector
|
Exercise / conversionCommon Stock | 2,129 | $72.14 | $153,586.06 |
DisclosureSEC source: 0001209191-23-004816 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 21:07 UTC |
Lee YuchunDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 442 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-004005 · doc4.xml · derivative · entry 6 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,558 Underlying: Common Stock · 442 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 21:07 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 442 | $312.17 | $137,979.14 |
DisclosureSEC source: 0001209191-23-004005 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $312.17 (range $312.00 to $312.53). Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 21:07 UTC |
Lee YuchunDirector
|
Exercise / conversionCommon Stock | 442 | $72.14 | $31,885.88 |
DisclosureSEC source: 0001209191-23-004005 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:07 UTC |
Lee YuchunDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-004005 · doc4.xml · derivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 4,000 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:07 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 4,000 | $312.03 | $1,248,120.00 |
DisclosureSEC source: 0001209191-23-004005 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $312.03 (range $312.00 to $312.14). Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:07 UTC |
Lee YuchunDirector
|
Exercise / conversionCommon Stock | 4,000 | $72.14 | $288,560.00 |
DisclosureSEC source: 0001209191-23-004005 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 21:07 UTC |
MCKENZIE DIANADirector
|
GrantDeferred Stock Units · Derivative | 100.53 | $298.42 | $30,000.16 |
DisclosureSEC source: 0001209191-23-003703 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,027.368 Underlying: Common Stock · 100.53 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 21:15 UTC |
SACHS BRUCE IDirector
|
GrantDeferred Stock Units · Derivative | 146.606 | $298.42 | $43,750.16 |
DisclosureSEC source: 0001209191-23-003726 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,268.774 Underlying: Common Stock · 146.606 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 21:23 UTC |
Upadhyay SuketuDirector
|
GrantDeferred Stock Units · Derivative | 96.341 | $298.42 | $28,750.08 |
DisclosureSEC source: 0001209191-23-003744 · doc4.xml · derivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234.996 Underlying: Common Stock · 96.341 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 21:08 UTC |
Arbuckle Stuart AEVP, COO
|
GrantCommon Stock | 12,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060339 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,031 F1 · shares: Restricted stock unit award that vests on 07/01/2025. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:08 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 34 | $308.61 | $10,492.74 |
DisclosureSEC source: 0000899243-22-036184 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,077 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:40 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,303 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0000899243-22-035443 · doc4.xml · derivative · entry 9 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,304 Underlying: Common Stock · 1,303 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2019. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:40 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 83 | $306.57 | $25,445.31 |
DisclosureSEC source: 0000899243-22-035443 · doc4.xml · nonDerivative · entry 8 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,077 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $306.57 (range $306.45 to $307.22). Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:40 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 140 | $305.39 | $42,754.60 |
DisclosureSEC source: 0000899243-22-035443 · doc4.xml · nonDerivative · entry 7 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,160 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $305.39 (range $305.38 to $305.39). Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:40 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 280 | $304.58 | $85,282.40 |
DisclosureSEC source: 0000899243-22-035443 · doc4.xml · nonDerivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,300 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $304.58 (range $304.14 to $304.91). Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:40 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 261 | $303.21 | $79,137.81 |
DisclosureSEC source: 0000899243-22-035443 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,580 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $303.21 (range $302.89 to $303.45). Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:40 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 189 | $301.99 | $57,076.11 |
DisclosureSEC source: 0000899243-22-035443 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,841 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $301.99 (range $301.84 to $302.20). Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:40 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 210 | $300.96 | $63,201.60 |
DisclosureSEC source: 0000899243-22-035443 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,030 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $300.96 (range $300.54 to $301.18). Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:40 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 140 | $299.72 | $41,960.80 |
DisclosureSEC source: 0000899243-22-035443 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,240 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $299.72 (range $299.46 to $299.97). Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:40 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionCommon Stock | 1,303 | $187.53 | $244,351.59 |
DisclosureSEC source: 0000899243-22-035443 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:05 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 22 | $317.77 | $6,990.94 |
DisclosureSEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 8 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,104 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $317.77 (range $317.56 to $317.82). Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:05 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 10 | $315.68 | $3,156.80 |
DisclosureSEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 7 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,126 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:05 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 12 | $314.43 | $3,773.16 |
DisclosureSEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 6 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,136 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $314.43 (range $314.42 to $314.48). Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:05 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 81 | $313.37 | $25,382.97 |
DisclosureSEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 5 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,148 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $313.37 (range $312.98 to $313.97). Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:05 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 100 | $312.40 | $31,240.00 |
DisclosureSEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 4 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,229 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $312.40 (range $311.98 to $312.90). Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:05 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 39 | $311.17 | $12,135.63 |
DisclosureSEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 3 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,329 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $311.17 (range $310.51 to $311.45). Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:05 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 56 | $310.10 | $17,365.60 |
DisclosureSEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,368 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $310.10 (range $309.50 to $310.48). Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:05 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
Tax withholdingCommon Stock | 768 | $312.84 | $240,261.12 |
DisclosureSEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,424 Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 20:05 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 621 | $310.00 | $192,510.00 |
DisclosureSEC source: 0000899243-22-034249 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,040 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 20:11 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 288 | $301.84 | $86,929.92 |
DisclosureSEC source: 0000899243-22-033880 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,192 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $301.84 (range $301.14 to $301.98). Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 20:11 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 1,503 | $300.02 | $450,930.06 |
DisclosureSEC source: 0000899243-22-033880 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,480 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $300.02 (range $300.00 to $300.14). Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 20:25 UTC |
MCKENZIE DIANADirector
|
GrantDeferred Stock Units · Derivative | 101.072 | $296.82 | $30,000.19 |
DisclosureSEC source: 0000899243-22-033743 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,926.838 Underlying: Common Stock · 101.072 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 20:27 UTC |
SACHS BRUCE IDirector
|
GrantDeferred Stock Units · Derivative | 147.396 | $296.82 | $43,750.08 |
DisclosureSEC source: 0000899243-22-033744 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,122.168 Underlying: Common Stock · 147.396 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 20:30 UTC |
Upadhyay SuketuDirector
|
GrantDeferred Stock Units · Derivative | 96.861 | $296.82 | $28,750.28 |
DisclosureSEC source: 0000899243-22-033745 · doc4.xml · derivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138.655 Underlying: Common Stock · 96.861 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:10 UTC |
Biller JonathanEVP and Chief Legal Officer
|
GrantCommon Stock | 5,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-031641 · doc4.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,294 F1 · shares: Restricted stock unit award that vests in installments beginning on 10/01/2022. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:36 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 300 | $305.57 | $91,671.00 |
DisclosureSEC source: 0000899243-22-029023 · doc4.xml · nonDerivative · entry 6 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,605 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $305.57 (range $305.55 to $305.58). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:36 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 1,743 | $305.01 | $531,632.43 |
DisclosureSEC source: 0000899243-22-029023 · doc4.xml · nonDerivative · entry 5 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,905 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $305.01 (range $304.54 to $305.53). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:36 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 700 | $303.99 | $212,793.00 |
DisclosureSEC source: 0000899243-22-029023 · doc4.xml · nonDerivative · entry 4 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,648 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $303.99 (range $303.48 to $304.46). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:36 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 100 | $302.35 | $30,235.00 |
DisclosureSEC source: 0000899243-22-029023 · doc4.xml · nonDerivative · entry 3 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,348 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:36 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 698 | $301.63 | $210,537.74 |
DisclosureSEC source: 0000899243-22-029023 · doc4.xml · nonDerivative · entry 2 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,448 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $301.63 (range $301.23 to $302.01). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:36 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 206 | $300.26 | $61,853.56 |
DisclosureSEC source: 0000899243-22-029023 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,146 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $300.26 (range $300.00 to $300.28). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:39 UTC |
Arbuckle Stuart AEVP, COO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,571 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0000899243-22-029030 · doc4.xml · derivative · entry 9 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,571 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:39 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 6,948 | $305.38 | $2,121,780.24 |
DisclosureSEC source: 0000899243-22-029030 · doc4.xml · nonDerivative · entry 7 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,278 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $305.38 (range $305.13 to $305.83). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:39 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 6,990 | $304.67 | $2,129,643.30 |
DisclosureSEC source: 0000899243-22-029030 · doc4.xml · nonDerivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,226 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $304.67 (range $304.13 to $305.12). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:39 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 2,339 | $303.78 | $710,541.42 |
DisclosureSEC source: 0000899243-22-029030 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,216 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $303.78 (range $303.13 to $304.09). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.